ArticleAnnals of surgical oncology2019
Long-Term Oncologic Outcomes After Isolated Limb Infusion for Locoregionally Metastatic Melanoma: An International Multicenter Analysis.
Article in Annals of surgical oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 46 citations in OpenAlex.
- The Evolving Role of Intralesional Therapy in In-Transit Melanoma.Current oncology (Toronto, Ont.) · 2026Review
- A phase 1 study of intra-arterial CBL0137 in extremity melanomas and sarcomas.Surgical oncology · 2025Article
- Review
- Oncolytic intralesional therapy for metastatic melanoma.Clinical & experimental metastasis · 2024Review
- Isolated hyperthermic perfusions for cutaneous melanoma in-transit metastasis of the limb and uveal melanoma metastasis to the liver.Clinical & experimental metastasis · 2024Review
- Review
- Management of acral lentiginous melanoma: current updates and future directions.Frontiers in oncology · 2024Review
- Great Debate: Limb Infusion for Melanoma: A Thing of the Past?Annals of surgical oncology · 2023Article
- The Diagnosis and Management of Cutaneous Metastases from Melanoma.International journal of molecular sciences · 2023Review
- Article
- Management of In-Transit Metastases.Current oncology reports · 2022Review
- In-transit metastatic cutaneous melanoma: current management and future directions.Clinical & experimental metastasis · 2022Review
- Malignant melanoma: evolving practice management in an era of increasingly effective systemic therapies.Current problems in surgery · 2022Review
- Molecular Aspects of the Isolated Limb Infusion Procedure.Biomedicines · 2021Review
- Immunotherapy for Melanoma.Advances in experimental medicine and biology · 2021Article
- Oncologic Outcomes After Isolated Limb Infusion for Advanced Melanoma: An International Comparison of the Procedure and Outcomes Between the United States and Australia.Annals of surgical oncology · 2020Article
- ASO Author Reflections: Return to Isolated Limb Infusion for In-Transit Melanoma.Annals of surgical oncology · 2020Article
- Injectable Therapies for Regional Melanoma.Surgical oncology clinics of North America · 2020Review
- Surgical Considerations and Systemic Therapy of Melanoma.The Surgical clinics of North America · 2020Review
- Intra-arterial perfusion-based therapies for regionally metastatic cutaneous and uveal melanoma.Melanoma management · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors at 13 institutions in 2 countries.
Funding
Abstract
backgroundIsolated limb infusion (ILI) is a minimally invasive procedure for delivering high-dose regional chemotherapy to patients with locally advanced or in-transit melanoma located on a limb. The current international multicenter study evaluated the perioperative and long-term oncologic outcomes for patients who underwent ILI for stage 3B or 3C melanoma.
methodsPatients undergoing a first-time ILI for stage 3B or 3C melanoma (American Joint Committee on Cancer [AJCC] 7th ed) between 1992 and 2018 at five Australian and four United States of America (USA) tertiary referral centers were identified. The primary outcome measures included treatment response, in-field (IPFS) and distant progression-free survival (DPFS), and overall survival (OS).
resultsA total of 687 first-time ILIs were performed (stage 3B: n = 383, 56%; stage 3C; n = 304, 44%). Significant limb toxicity (Wieberdink grade 4) developed in 27 patients (3.9%). No amputations (grade 5) were performed. The overall response rate was 64.1% (complete response [CR], 28.9%; partial response [PR], 35.2%). Stable disease (SD) occurred in 14.5% and progressive disease (PD) in 19.8% of the patients. The median follow-up period was 47 months, with a median OS of 38.2 months. When stratified by response, the patients with a CR or PR had a significantly longer median IPFS (21.9 vs 3.0 months; p < 0.0001), DPFS (53.6 vs 12.7 months; p < 0.0001), and OS (46.5 vs 24.4 months; p < 0.0001) than the nonresponders (SD + PD).
conclusionThis study is the largest to date reporting long-term outcomes of ILI for locoregionally metastatic melanoma. The findings demonstrate that ILI is effective and safe for patients with stage 3B or 3C melanoma confined to a limb. A favorable response to ILI is associated with significantly longer IFPS, DPFS, and OS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.